Statistics from Altmetric.com
We read with great interest the article by Murakami et al,1 who performed a randomised, double-blinded study of vonoprazan-based Helicobacter pylori (H. pylori) eradication therapy. They showed high success rates for vonoprazan-based first-line and second-line H. pylori treatments, with eradication rates of 92.6% and 98%, respectively. However, the study populations of second-line therapy included patients for whom both lansoprazole-based and vonoprazan-based first-line treatments failed, and those for whom vonoprazan-based first-line therapy failed numbered only 14. In terms of second-line therapy, we think that the eradication rate in patients for whom vonoprazan-based first-line therapy failed is more important.
We conducted …
Contributors YK collected the data and wrote the manuscript; KT, YK, TS, SA, IT and SO collected the data; MT and MS collected the data and polished the manuscript.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.